Previous 10 | Next 10 |
Gainers: Virpax Pharmaceuticals (NASDAQ:VRPX) +96%, Sesen Bio (NASDAQ:SESN) +28%, Terns Pharmaceuticals (NASDAQ:TERN) +16%, 23andMe (NASDAQ:ME) +16%, NanoVibronix (NASDAQ:NAOV) +9%. Losers: Qualigen Therapeutics (NASDAQ:QLGN) -16%, Sema4 ...
Shares of genetic data miner 23andMe Holding (NASDAQ: ME) surged in early trading Tuesday -- up 11.5% as of 10:10 a.m. EDT. If you own shares of the recent special purpose acquisition company ( SPAC ) IPO, you can thank Credit Suisse for that. Image source: Getty Ima...
23andMe Holding Co. (ME) Q1 2022 Earnings Conference Call August 13, 2021 11:00 AM ET Company Participants Wade Walke – Vice President-Investor Relations Anne Wojcicki – Co-Founder and Chief Executive Officer Steve Schoch – Chief Financial Officer Kenneth Hillan – ...
Several noteworthy stocks are losing ground in midday trading Friday following the release of poorly received quarterly results. ContextLogic (NASDAQ:WISH), SoFi Technologies (NASDAQ:SOFI), Tattooed Chef (NASDAQ:TTCF) and 23andMe (NASDAQ:ME) all declined on earnings news. However, investors a...
First quarter revenue up 23% over prior year Strong cash balance of $770 million Continuing to advance therapeutics portfolio to drive future revenue growth SUNNYVALE, Calif., Aug. 13, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a...
SUNNYVALE, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial results for the fiscal year 2022 first quarter before the market opens on Friday, ...
monsitj/iStock via Getty Images Earnings dominated the headlines on Tuesday, especially with several big names in the technology sector reporting after the close. However, one of the day's biggest stories involved investors ignoring better-than-expected quarterly figures. The electric vehicle...
23andMe Holding Co. is the leading direct-to-consumer genetic testing company entering drug development with data on 11.3M Genotyped Customers and +$696M in SPAC funding. 23andMe's core products include a suite of D2C genetic reports covering ancestry, genetic health risks, carrier st...
Freshly listed on the NASDAQ following a business combination with VG Acquisition Corp, a special purpose acquisition company (SPAC), the consumer genetic-testing maven 23andMe (NASDAQ: ME) is at the very start of its growth story. Since trading as a combined entity commenced on Jun...
On June 16, special purpose acquisition company (SPAC) Virgin Group Acquisition completed its merger with consumer genetics company 23andMe (NASDAQ: ME) . The deal funded the latter with $592 million in cash at a total enterprise valuation of $3.5 billion. Investors were e...
News, Short Squeeze, Breakout and More Instantly...
SOUTH SAN FRANCISCO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial resu...
SUNNYVALE, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading genetic health and biopharmaceutical company, in collaboration with 20 lung cancer advocacy organizations, today announced a new study to help advance research in lung cancer. The focus of the Lun...